{"pub": "marketwatch", "url": "https://marketwatch.com/articles/biotech-ipos-offer-a-lesson-in-risk-management-51569839400", "downloaded_at": "2019-09-30 10:45:28.189672+00:00", "title": "Biotech IPOs Are Risky Business. Here\u2019s How To Do a Deal Right", "language": "en", "text": "David Schenkein, a general partner at GV, the venture-capital arm of Google parent Alphabet (ticker: GOOGL) and co-head of GV\u2019s life science team, has been on both sides of the board room. In 2013, Schenkein, a medical oncologist, took Agios Pharmaceuticals (AGIO) public as its CEO. In a recent interview with Barron\u2019s, Schenkein, a panelist on Barron\u2019s biotech roundtable, discussed what he learned from his experience at Agios, where he remains executive chairman. Agios shares have returned more than 90% since their IPO.\n\n...", "description": "GV partner David Schenkein took Agios Pharmaceuticals public in 2013. Here\u2019s how the experience informs his work as a venture capitalist.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DG004_DavidQ_OR_20190927162021.jpg", "published_at": "2019-09-30"}